Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway

International Journal of Molecular Medicine

Volumn 32, Issue 1, 2013, Pages 79-84

  Liao, Jun ^a   Xu, Teng ^a   Zheng, Jia Xuan ^a   Lin, Jiu Mao ^a   Cai, Qiao Yan ^a   Yu, De Biao ^a   Peng, Jun ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Chinese medicine; Hepatocellular carcinoma; Janus activated kinase 1; Nitidine chloride; Proliferation; Signal transducer and activator of transcription 3

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLINE; JANUS KINASE 1; NITIDINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOPHENANTHRIDINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 1; LIVER NEOPLASMS; MICE; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878236643     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1358     Document Type: Article

References (44)

1. Ferenci P, Fried M, Labrecque D, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44: 239-245, 2010.
2. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
3. Bridges JF, Dong L, Gallego G, Blauvelt BM, Joy SM and Pawlik TM: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res 12: 376, 2012.
4. Wörns MA and Galle PR: Future perspectives in hepatocellular carcinoma. Dig Liver Dis 42 (Suppl 3): S302-S309, 2010.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
6. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430, 2001. (Pubitemid 32844200)
7. Levin B and Amos C: Therapy of unresectable hepatocellular carcinoma. N Engl J Med 332: 1294-1296, 1995.
8. Abou-Alfa GK, Huitzil-Melendez F-D, O'Reilly EM and Saltz LB: Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2: 64-70, 2008.
9. Boos G and Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116: 7-16, 2000. (Pubitemid 30440762)
10. Auyeung KK and Ko JK: Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. Int J Mol Med 24: 571-577, 2009.
11. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
12. Newman DJ, Cragg GM and Snader KM: The influence of natural products upon drug discovery. Nat Prod Rep 17: 215-234, 2000. (Pubitemid 30390787)
13. Yamaoka K, Saharinen P, Pesu M, Holt VE III, Silvennoinen O and O'Shea JJ: The Janus kinases (Jaks). Genome Biol 5: 253, 2004.
14. Aaronson DS and Horvath CM: A road map for those who don't know JAK-STAT. Science 296: 1653-1655, 2002. (Pubitemid 34579157)
15. O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 (Suppl): S121-S131, 2002. (Pubitemid 34457857)
16. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994. (Pubitemid 24217131)
17. Kisseleva T, Bhattacharya S, Braunstein J and Schindler C: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1-24, 2002. (Pubitemid 34246317)
18. Liu L, Nam S, Tian Y, et al: 6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 71: 3972-3979, 2011.
19. Bromberg J and Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473, 2000. (Pubitemid 30339202)
20. Xu Q, Briggs J, Park S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560, 2005. (Pubitemid 43119350)
21. Liao J, Ke M, Xu T and Lin L: Electroacupuncture inhibits apoptosis in annulus fibrosis cells through suppression of the mitochondria-dependent pathway in a rat model of cervical intervertebral disc degradation. Genet Mol Biol 35: 686-692, 2012.
22. Yarani R, Mansouri K, Mohammadi-Motlagh HR, Mahnam A and Emami Aleagha MS: In vitro inhibition of angiogenesis by hydroalcoholic extract of oak (Quercus infectoria) acorn shell via suppressing VEGF, MMP-2, and MMP-9 secretion. Pharm Biol 51: 361-368, 2012.
23. Chen J, Wang J, Lin L, et al: Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther 11: 277-287, 2012
24. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002. (Pubitemid 35177340)
25. Calvisi DF, Pascale RM and Feo F: Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2: 217-236, 2007. (Pubitemid 47558825)
26. Imada K and Leonard WJ: The Jak-STAT pathway. Mol Immunol 37: 1-11, 2000. (Pubitemid 30316189)
27. Bencao Z (ed): Chinese Herbal Medicine. Chinese Edition. Shanghai Science and Technology Publishing House, Shanghai, 1996.
28. Pan X, Han H, Wang L, et al: Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett 313: 181-191, 2011.
29. Wang Z, Jiang W, Zhang Z, Qian M and Du B: Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J Ethnopharmacol 144: 145-150, 2012.
30. Liu LM and Liu HG: Anti-hepatoma activity of nitidine chloride and its effect on topoisomerase. Chin Pharmacol Bull 4: 497-500, 2010 (In Chinese).
31. Cushman M, Mohan P and Smith EC: Synthesis and biological activity of structural analogs of the anticancer benzophenanthridine alkaloid nitidine chloride. J Med Chem 27: 544-547, 1984. (Pubitemid 14133747)
32. Adams J and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337, 2007. (Pubitemid 46328466)
33. Cai Q, Lin J, Wei L, et al: Hedyotis diffusa Willd inhibits colorectal cancer growth in vivo via inhibition of STAT3 signaling pathway. Int J Mol Sci 13: 6117-6128, 2012.
34. Hall C, Troutman SM, Price DK, Figg WD and Kang MH: Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms. Clin Genitourin Cancer 11: 10-19, 2013.
35. Paul-Samojedny M, Kokocińska D, Samojedny A, et al: Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta 1741: 25-29, 2005.
36. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
37. Chae HD, Kim J and Shin DY: NF-Y binds to both G1- and G2-specific cyclin promoters; a possible role in linking CDK2/Cyclin A to CDK1/Cyclin B. BMB Rep 44: 553-557, 2011.
38. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
39. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM and Firestone GL: Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23: 370-379, 2012.
40. Zafonte BT, Hulit J, Amanatullah DF, et al: Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Front Biosci 5: D938-D961, 2000.
41. Domagala W, Welcker M, Chosia M, et al: p21/WAF1/Cip1 expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch 439: 132-140, 2001. (Pubitemid 32758906)
42. Whang-Peng J, Cheng AL, Hsu C and Chen CM: Clinical development and future direction for the treatment of hepatocellular carcinoma. J Exp Clin Med 2: 93-103, 2010.
43. Fracchiolla N, Capaccio P, Carboni N, et al: Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas. Anticancer Res 19: 1043-1051, 1999. (Pubitemid 29257536)
44. Diaz N, Minton S, Cox C, et al: Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 12: 20-28, 2006. (Pubitemid 43166171)